DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

Merck & Co., Inc. (NYSE: MRK)



company name or ticker
Company Photos
(Click to zoom)

An 80/20 Filter On How The DJIA Weathered The Week

Did This Clinical Study Just Show Merck's Best-Selling Drug the Door?

Are DPP-4 inhibitors like Januvia on their way out? A new long-term study from partners Eli Lilly and Boehringer Ingelheim suggests it's a possibility.

The Zacks Analyst Blog Highlights: Merck & Co, Apple, Visa, Microsoft and Intel

Novo Nordisk to Start PIONEER Program on Semaglutide

5 Stocks That Led Dow to 3rd Biggest Gain

JNJ’s Splenda Sale Shouldn’t Be A Concern For Investors

Eli Lilly's Diabetes Drug May Halt Heart Disease

Eli Lilly's Jardiance was shown to reduce the risk of heart attack and stroke in diabetics.

The 4 Stocks That Boosted the DJIA on Wednesday

Trade-Ideas: Merck (MRK) Is Today's "Dead Cat Bounce" Stock

Short Sellers Have Mixed Feelings on Major Pharma

See More Articles...